Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
1.
J Korean Med Sci ; 38(48): e382, 2023 Dec 11.
Artigo em Inglês | MEDLINE | ID: mdl-38084026

RESUMO

The current emergence of the coronavirus disease 2019 (COVID-19) pandemic and the possible side effects of COVID-19 mRNA vaccination remain worrisome. Few cases of vaccination-related side effects, such as vasculitis, have been reported. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a type of vasculitis characterized by the histological richness of eosinophils, asthma, polyneuropathy, sinusitis, and skin or lung involvement. Here, we report the first case of new onset EGPA following COVID-19 vaccination in Korea. A 71-year old woman developed a skin rash and presented with progressive weakness of the upper and lower extremities after the BNT162b2 vaccination (Pfizer-BioNTech). She was diagnosed with EGPA and her symptoms improved after systemic steroid and immunosuppressant therapy. Although it is very rare, clinicians should be aware that EGPA may occur after COVID-19 vaccination.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Síndrome de Churg-Strauss , Granulomatose com Poliangiite , Idoso , Feminino , Humanos , Vacina BNT162 , Síndrome de Churg-Strauss/diagnóstico , Síndrome de Churg-Strauss/etiologia , Síndrome de Churg-Strauss/tratamento farmacológico , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Granulomatose com Poliangiite/diagnóstico , Granulomatose com Poliangiite/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA